The Relationship between the Subchondral Bone Density Distribution and Glenoid Depth: An -In-Vivo Pilot Study of Male Total Shoulder Arthroplasty Subjects

2014 ◽  
Vol 23 (9) ◽  
pp. e240-e241
Author(s):  
Peter Simon ◽  
Anil K. Gupta ◽  
Ioannis Pappau ◽  
Michael M. Hussey ◽  
Brandon G. Santoni ◽  
...  
2015 ◽  
Vol 24 (3) ◽  
pp. 416-424 ◽  
Author(s):  
Peter Simon ◽  
Anil Gupta ◽  
Ioannis Pappou ◽  
Michael M. Hussey ◽  
Brandon G. Santoni ◽  
...  

2019 ◽  
Vol 32 (03) ◽  
pp. 207-214
Author(s):  
Walter Dingemanse ◽  
Ingrid Gielen ◽  
Henri van Bree ◽  
Magdalena Müller-Gerbl ◽  
Nikola Krstić ◽  
...  

Objective Subchondral bone density distribution can be used to study joint biomechanics non-invasively. Differences in joint loading between related species can aid in the understanding of joint loading and the development of certain types of orthopaedic pathology. This study was conducted to evaluate density distribution in the subchondral bone of the talus of different Canidae species, as a parameter reflecting the long-term joint loading in the tarsocrural joint. Materials and Methods The tarsal joints of cadaveric dogs of different breeds were included, that is, German Shepherd (n = 5), Bouvier des Flandres (n = 3) and Labrador Retriever (n = 6).Additionally, golden jackals (n = 5) (Canis aureus) and wolves (n = 5) (Canis lupus) were included. Consecutive computed tomography slices were made and the subchondral bone density distribution was evaluated using computer tomographic osteoabsorptiometry. Different breeds and species were visually compared. Results Differences were found in the subchondral bone density distribution of the talus between breeds and between species (Canis familiaris, Canis lupus and Canis aureus). Discussion and Conclusion Based on the density distribution, there are differences in loading conditions of the tarsocrural joint in different species of Canidae. The joint loading distribution is very similar between dogs of the same breed and within the same species. Although between-breed differences can be explained by conformational differences, the between-species differences remain subject to further research.


2016 ◽  
Vol 12 (1) ◽  
Author(s):  
W. Dingemanse ◽  
M. Müller-Gerbl ◽  
I. Jonkers ◽  
J. Vander Sloten ◽  
H. van Bree ◽  
...  

2011 ◽  
Vol 41 (6) ◽  
pp. 677-683 ◽  
Author(s):  
David A. Wright ◽  
Michael Meguid ◽  
Omri Lubovsky ◽  
Cari M. Whyne

2013 ◽  
Vol 25 (3) ◽  
pp. 1107-1114 ◽  
Author(s):  
W. D. Burnett ◽  
S. A. Kontulainen ◽  
C. E. McLennan ◽  
D. J. Hunter ◽  
D. R. Wilson ◽  
...  

Author(s):  
John R Burnett ◽  
Samuel D Vasikaran

Atherosclerotic heart disease and osteoporosis are both diseases of old age. Evidence is accumulating for a link between vascular and bone disease. Calcification is a common feature of atherosclerotic plaques, and osteoporosis is associated with both atherosclerosis and vascular calcification. However, the relationship of vascular calcification to the pathogenesis of atherosclerosis remains incompletely understood. Hormone replacement therapy has beneficial effects in the prevention of both atherosclerosis and osteoporosis. Bisphosphonates inhibit bone resorption and are used in the treatment of osteoporosis, whereas the statins inhibit cholesterol biosynthesis and are used for the treatment of atherosclerosis. We have reviewed recent advances in the knowledge of the actions of bisphosphonates and statins at the cellular, molecular and end-organ levels in order to examine the relationship between cardiovascular disease and osteoporosis and to explore the link between lipids and bones. These studies suggest that the mechanism of actions of these two classes of drugs at the cellular level may not be mutually exclusive. There are some early clinical data to complement these findings, suggesting that statins increase bone density and bisphosphonates may have a beneficial effect in vivo on plasma lipid levels and on the atherosclerotic process. Properly designed prospective studies that examine the effect of statins on bone density and fractures, as well as the effects of bisphosphonates on lipid profiles, atherosclerotic progression and cardiovascular morbidity and mortality are needed to define clearly the clinical effects and potential new roles for these agents.


Sign in / Sign up

Export Citation Format

Share Document